245 related articles for article (PubMed ID: 27620894)
1. Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
Choi IY; Lee P; Hughes AJ; Denney DR; Lynch SG
Mult Scler; 2017 Jun; 23(7):956-962. PubMed ID: 27620894
[TBL] [Abstract][Full Text] [Related]
2. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.
Choi IY; Lee SP; Denney DR; Lynch SG
Mult Scler; 2011 Mar; 17(3):289-96. PubMed ID: 20921235
[TBL] [Abstract][Full Text] [Related]
3. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
4. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
[TBL] [Abstract][Full Text] [Related]
5. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
Abdel-Aziz K; Schneider T; Solanky BS; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Peters AL; Day BL; Thompson AJ; Ciccarelli O
Brain; 2015 Jun; 138(Pt 6):1568-82. PubMed ID: 25863355
[TBL] [Abstract][Full Text] [Related]
6. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
[TBL] [Abstract][Full Text] [Related]
7. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
8. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
9. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
12. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
[TBL] [Abstract][Full Text] [Related]
13. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
14. Rehabilitation with neuromuscular electrical stimulation leads to functional gains in ambulation in patients with secondary progressive and primary progressive multiple sclerosis: a case series report.
Wahls TL; Reese D; Kaplan D; Darling WG
J Altern Complement Med; 2010 Dec; 16(12):1343-9. PubMed ID: 21138391
[TBL] [Abstract][Full Text] [Related]
15. Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
MacMillan EL; Tam R; Zhao Y; Vavasour IM; Li DK; Oger J; Freedman MS; Kolind SH; Traboulsee AL
Mult Scler; 2016 Jan; 22(1):112-6. PubMed ID: 26014604
[TBL] [Abstract][Full Text] [Related]
16. Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy.
Mandal PK; Tripathi M; Sugunan S
Biochem Biophys Res Commun; 2012 Jan; 417(1):43-8. PubMed ID: 22120629
[TBL] [Abstract][Full Text] [Related]
17. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.
Rocca MA; Sormani MP; Rovaris M; Caputo D; Ghezzi A; Montanari E; Bertolotto A; Laroni A; Bergamaschi R; Martinelli V; Comi G; Filippi M
Brain; 2017 Nov; 140(11):2814-2819. PubMed ID: 29053836
[TBL] [Abstract][Full Text] [Related]
18. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
20. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
